Asbjørn Mohr D.
- Country
- Denmark
- Department
- Department of Gastroenterology and Hepatology
Research Overview
- Efficacy and Safety of Tezepelumab in Eosinophilic Esophagitis: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
- Evaluation of Finerenone in the Management of Early Diabetic Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Naldemedine on Opioid-Induced Bowel Dysfunction in Patients Receiving Tramadol: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 2 of 51 partner sites.
Specializations
Gastrointestinal Disorders
This investigator specializes in studying eosinophilic esophagitis (EoE), focusing on inflammatory responses in the esophagus and immune-mediated reactions to food and environmental triggers.
- Esophageal dysfunction management
- Inflammatory response patterns
- Immune-mediated conditions
The research extends to evaluating novel therapeutic approaches for chronic inflammatory esophageal conditions.
Digestive System Disorders
The investigator conducts research into opioid-induced bowel dysfunction (OIBD), examining gastrointestinal transit and motility patterns.
- Gastrointestinal motility assessment
- Colonic function studies
- Therapeutic interventions for OIBD
Particular attention is given to understanding medication effects on digestive system function and secretion patterns.
Diabetic Complications
Research focuses on cardiovascular autonomic neuropathy (CAN) in type 2 diabetes patients, investigating disease modification and neuropathy progression.
- Cardiac function assessment
- Fibrosis and inflammation markers
- Early-stage neuropathy evaluation
The research encompasses long-term monitoring of diabetic complications and therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.